CLAIMS

What is claimed is:

1. A method of treating, preventing or managing lupus which comprises administering to a patient in need of such treatment a therapeutically or prophylactively effective amount of clofarabine or a pharmaceutically acceptable salt, stereoisomer, solvate, hydrate, clathrate, prodrug or metabolite thereof.

2. The method of claim 1 wherein the lupus is cutaneous lupus erythematosus, chronic cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus, acute lupus erythematosus, systemic lupus erythematosus, drug-induced lupus, neonatal lupus, discoid lupus, or lupus-in-overlap.

3. The method of claim 1 wherein the patient is a mammal.

4. The method of claim 3 wherein the mammal is a human.

5. The method of claim 4 wherein the human is an adult.

6. The method of claim 4 wherein the human is an adolescent.

7. The method of claim 4 wherein the human is a child.

8. The method of claim 4 wherein the human is an infant.

9. The method of claim 1 further comprising the administration of an additional therapeutic agent.

10. The method of claim 10 wherein the additional therapeutic agent is an antibiotic, an antiemetic agent, an antidepressant, and antifungal agent, an antiinflammatory agent, an antiviral agent, an immunomodulatory agent, an antimalarial agent, a β-interferon, an alkylating agent, a hormone or a cytokine.

11. The method of claim 1 wherein the therapeutically or prophylactively effective amount is greater than 0.01 mg/kg/day.

12. The method of claim 1 wherein the therapeutically or prophylactively effective amount of clofarabine is from about 5 mg/kg/day to about 75 mg/kg/day.

13. The method of claim 12 wherein the therapeutically or prophylactively effective amount of clofarabine is from about 20 mg/kg/day to about 60 mg/kg/day.

14. The method of claim 13 wherein the therapeutically or prophylactively effective amount of clofarabine is from about 40 mg/kg/day to about 50 mg/kg/day.

15. The method of claim 1 wherein the therapeutically or prophylactively effective amount of clofarabine is administered parenterally.

16. The method of claim 1 wherein the therapeutically or prophylactively effective amount of clofarabine is administered orally.

17. A pharmaceutical composition for the treatment of lupus which comprises about 0.1mg to about 1000 mg of clofarabine, or a pharmaceutically acceptable salt, hydrate, clathrate, solvate, prodrug, metabolite or stereoisomer thereof and a pharmaceutically acceptable carrier.

18. A pharmaceutical composition for treatment of lupus which comprises a therapeutically effective amount of clofarabine which sufficient to treat lupus for which is insufficent to case adverse affects associated with purine nucleosides.

19. A pharmaceutical composition for treatment of lupus which comprises a therapeutically effective amount of clofarabine and other immunomodulatory agent which sufficient to treat lupus for which is insufficent to case adverse affects associated with purine nucleosides.